Evidence map›Paper›PMID 35303246›Full record

ArticleLa Radiologia medica2022

SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM).

Antonio Orlacchio, Carlo Guastoni, Giordano Domenico Beretta, Laura Cosmai, Michele Galluzzo, Stefania Gori, Emanuele Grassedonio, Lorena Incorvaia, Carmelita Marcantoni, Giuseppe Stefano Netti and 8 more

Open access · hybridAbstract readConsensus Statement
In one paragraph

Article in La Radiologia medica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. FermentedRenal failure · 2024
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 1 country.

Antonio OrlacchioRadiology Unit, Department of Surgical Science, University of Rome "Tor Vergata", Rome, Italy. aorlacchio@uniroma2.it.ORCID http://orcid.org/0000-0002-7053-8813
Carlo GuastoniNephology Unit, ASST Ovest Milanese, Legnano, Italy.
Giordano Domenico BerettaDepartment of Oncology, Humanitas Gavazzeni, Bergamo, Italy.
Laura CosmaiNephology Unit, Azienda Ospedaliera San Carlo Borromeo di Milano, Milan, Italy.
Michele GalluzzoEmergency Radiology, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
Stefania GoriDepartment of Oncology, IRCC Ospedale Sacro Cuore Don Calabria, Negrar Valpolicella, Italy.
Emanuele GrassedonioDepartment of Radiology, Policlinico Giaccone University, Palermo, Italy.
Lorena IncorvaiaDepartment of Oncology, University of Palermo, Palermo, Italy.
Carmelita MarcantoniNephology UnitSan Marco Hospital, Azienda Ospedaliero Universitaria, Catania, Italy.
Giuseppe Stefano NettiClinical Pathology, University of Foggia, Ospedali Riuniti, Foggia, Italy.
Matteo PassamontiRadiology Unit, Ospedale di Oglio Po. ASST Cremona, Cremona, Italy.
Camillo PortaOncology Unit, University of Bari, Bari, Italy.
Giuseppe ProcopioGenito-Urinary Medical Oncology, Fondazione Istituto Nazionale Tumori, Milano, Italy.
Mimma RizzoOncology Unit, Hospital Santa Chiara, Trento, Italy.
Silvia RomaRadiology Unit, Hospital F. Spaziani, Frosinone, Italy.
Laura RomaniniRadiology Unit, Ospedale di Cremona, ASST Cremona, Cremona, Italy.
Fulvio StaculDepartment of Radiology, Maggiore Hospital, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy.
Alice CasinelliEmergency Radiology, Policlinico Tor Vergata, Viale Oxford, 81, 00133, Rome, Italy.
Istituti Ospitalieri di Cremona · ITASST Melegnano e della Martesana · ITAzienda Ospedaliera Ospedale San Carlo Borromeo · ITAzienda Ospedaliera San Camillo-Forlanini · ITAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITAzienda Sanitaria Universitaria Integrata di Trieste · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITHumanitas Gavazzeni · ITOspedale Sacro Cuore Don Calabria · ITOspedale Santa Chiara · ITPoliclinico Tor Vergata · ITUniversity of Bari Aldo Moro · ITUniversity of Foggia · ITUniversity of Palermo · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing number of examinations and interventional radiological procedures that require the administration of contrast medium (CM) in patients at risk for advanced age and/or comorbidities highlights the problem of CM-induced renal toxicity. A multidisciplinary group consisting of specialists of different disciplines-radiologists, nephrologists and oncologists, members of the respective Italian Scientific Societies-agreed to draw up this position paper, to assist clinicians increasingly facing the challenges posed by CM-related renal dysfunction in their daily clinical practice.The major risk factor for acute renal failure following CM administration (post-CM AKI) is the preexistence of renal failure, particularly when associated with diabetes, heart failure or cancer.In accordance with the recent guidelines ESUR, the present document reaffirms the importance of renal risk assessment through the evaluation of the renal function (eGFR) measured on serum creatinine and defines the renal risk cutoff when the eGFR is < 30 ml/min/1.73 m2 for procedures with intravenous (i.v.) or intra-arterial (i.a.) administration of CM with renal contact at the second passage (i.e., after CM dilution with the passage into the pulmonary circulation).The cutoff of renal risk is considered an eGFR < 45 ml/min/1.73 m2 in patients undergoing i.a. administration with first-pass renal contact (CM injected directly into the renal arteries or in the arterial district upstream of the renal circulation) or in particularly unstable patients such as those admitted to the ICU.Intravenous hydration using either saline or Na bicarbonate solution before and after CM administration represents the most effective preventive measure in patients at risk of post-CM AKI. In the case of urgency, the infusion of 1.4% sodium bicarbonate pre- and post-CM may be more appropriate than the administration of saline.In cancer patients undergoing computed tomography, pre- and post-CM hydration should be performed when the eGFR is < 30 ml/min/1.73 m2 and it is also advisable to maintain a 5 to 7 days interval with respect to the administration of cisplatin and to wait 14 days before administering zoledronic acid.In patients with more severe renal risk (i.e., with eGFR < 20 ml/min/1.73 m2), particularly if undergoing cardiological interventional procedures, the prevention of post-CM AKI should be implemented through an internal protocol shared between the specialists who treat the patient.In magnetic resonance imaging (MRI) using gadolinium CM, there is a lower risk of AKI than with iodinated CM, particularly if doses < 0.1 mmol/kg body weight are used and in patients with eGFR > 30 ml/min/1.73 m2. Dialysis after MRI is indicated only in patients already undergoing chronic dialysis treatment to reduce the potential risk of systemic nephrogenic fibrosis.

Indexed as

Acute Kidney InjuryNephrologyRadiologyContrast MediaFemaleHumansKidneyMaleMedical OncologyRisk FactorsContrast MediaConsensusDiagnosticKidney injuryNephrologyNephrotoxicityOncologyRadiology

Identifiers

PMID35303246
PMCPMC9098565
OpenAlexW4220758999

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.